Recurrent aphthous oral ulcer
Conditions
Interventions
Thalidomide group:None
Thalidomide + erbium laser group:None
Sponsors
Suining Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Disease diagnosis: According to clinical symptoms, signs and necessary auxiliary examination by professional dentists, it was diagnosed as recurrent oral ulcer. 2. In terms of treatment: erbium laser combined with thalidomide therapy must be received. Among them, erbium laser treatment parameters should be clearly recorded within a reasonable and commonly used clinical range, such as wavelength, energy, pulse frequency, etc. The dosage and course of treatment of thalidomide should also be clearly recorded in medical records and conform to clinical treatment norms. 3. Physical condition: between 18 and 60 years old. This relatively narrow age range aims to reduce the significant differences in physiological functions, disease characteristics and treatment responses caused by excessive age differences, making the study results more targeted and comparable. At the same time, patients should have no serious systemic diseases, such as uncontrolled cardiovascular disease, diabetes, autoimmune diseases, etc., in order to rule out the interference of these diseases on the treatment effect of oral ulcer and inflammation level. 4. Medical records: Medical records were complete, covering basic information of patients (age, gender, course of disease, etc.), information related to oral ulcers (attack frequency, ulcer size, pain degree, etc.), detection results of inflammatory indicators before and after treatment (such as tumor necrosis factor-a, interleukin-6, interleukin-8, etc.), and evaluation of treatment effects (healing time, recurrence, etc.). Complete medical records are the basis of accurate retrospective analysis. If the medical records are missing key information, it will not meet the research requirements.
Exclusion criteria
Exclusion criteria: 1. Patients with serious systemic diseases: patients with serious cardiovascular diseases, such as unstable angina pectoris, uncontrolled severe arrhythmia, uncontrolled diabetes, and serious autoimmune diseases, such as systemic lupus erythematosus active stage and severe onset of rheumatoid arthritis 2. People with special physiological status: pregnant or lactating women are excluded. 3. Patients with allergies: Patients who are allergic to materials used in erbium laser therapy (such as specific coatings or auxiliary consumables for certain laser devices), or who are allergic to thalidomide are not eligible for inclusion. Anaphylaxis can cause additional symptoms and physical changes that interfere with the observation and analysis of the efficacy of the study regimen itself and changes in inflammation levels. 4. Other interfering factors: other drugs that may affect the efficacy of oral ulcers are used at the same time during treatment, such as immunomodulators and traditional Chinese medicine preparations with clear anti-inflammatory effects; Other special treatments that may interfere with the treatment of oral ulcers, such as recent local oral radiotherapy or use of special oral biologics, were also not eligible for inclusion. 5. Incomplete medical records: If the patient's medical records are missing key information, such as no clear detection results of inflammation indicators before and after treatment, or the erbium laser parameters, thalidomide dosage and course of treatment records are unclear, which cannot provide complete data support for the study, such medical records will also be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment effect, ulcer healing time, ulcer recurrence, pain score, and inflammatory factor levels; | — |
Countries
China
Contacts
Public ContactYang Lianjie
Suining Central Hospital
Outcome results
None listed